GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Long-Term Capital Lease Obligation

IXICO (LSE:IXI) Long-Term Capital Lease Obligation : £0.21 Mil (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is IXICO Long-Term Capital Lease Obligation?

IXICO's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was £0.21 Mil.

IXICO's quarterly Long-Term Capital Lease Obligation declined from Mar. 2023 (£0.32 Mil) to Sep. 2023 (£0.28 Mil) and declined from Sep. 2023 (£0.28 Mil) to Mar. 2024 (£0.21 Mil).

IXICO's annual Long-Term Capital Lease Obligation declined from Sep. 2021 (£0.52 Mil) to Sep. 2022 (£0.39 Mil) and declined from Sep. 2022 (£0.39 Mil) to Sep. 2023 (£0.28 Mil).


IXICO Long-Term Capital Lease Obligation Historical Data

The historical data trend for IXICO's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Long-Term Capital Lease Obligation Chart

IXICO Annual Data
Trend Sep13 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.05 0.52 0.39 0.28

IXICO Semi-Annual Data
Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.39 0.32 0.28 0.21

IXICO  (LSE:IXI) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

IXICO Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of IXICO's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


IXICO (LSE:IXI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
Address
15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines